Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Do you have a local show production that you'd like to list on BroadwayWorld to help spread the word, sell tickets to your show and to promote your theatre? You've found the right spot. List your show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback